IMT™ survival and quality of life data to be presentedBiomarker analyses from the ongoing Phase 3 study evaluating predictors ...
Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching targeted cell therapies designed specifically for patients with autoimmune diseases, ...
– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab abstracts ...
Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planned to Review RIDGE-1 Data ...
Please note: This item is from our archives and was published in 2022. It is provided for historical reference. The content may be out of date and links may no longer function. Tom King, CPA, has ...
Abstract accepted at the American Society of Clinical Oncology (ASCO) Annual Meeting - the world’s largest and most ...
Poster Presentation Title: No Association between Decreases in Serum Immunoglobulin Levels and Serious Infections with Long-Term Ublituximab Treatment in Patients with Relapsing Multiple Sclerosis ...
Anthropic just rolled out a new design tool, and it's hardly the only AI company that can help you whip up a chart in seconds ...
Vertical Data Inc. to highlight its vision for scalable AI infrastructure and capital solutions at a premier Wall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results